Replies to post #7255 on Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Another thing I don't understand: how an analyst can call for a move from $53 to $54 in 12 months and then list their buying recommendation as "overweight". That must look really odd to their customers.